Back to top
October 7, 2016
FDA Approves Lundbeck's New Drug
Treatments

The Food and Drug Administration (FDA) has approved Lundbeck’s Carnexiv™ (carbamazepine) injection as a short-term replacement therapy for oral carbamazepine formulations in adults with certain seizure types when oral administration is temporarily not feasible. Carnexiv will be the first available intravenous (IV) formulation of the antiepileptic drug (AED) carbamazepine, and Lundbeck plans to make it commercially available in the US in early 2017. Carnexiv is a short-term (≤7 days) intravenous replacement therapy for oral carbamazepine formulations that provides continuity of care for adult patients who are unable to take carbamazepine by mouth and have seizure types: partial seizures with complex symptomatology; generalized tonic-clonic seizures; and mixed seizure patterns.

Read the press release

Related News

June 19, 2018
Clinical Trial to Investigate the Efficacy and Clinical...

Read More
June 12, 2018
Generic Antiepileptic Drugs - Safe or Harmful in Patients...

Sufficient evidence indicates that most generics are bioequivalent to innovator AEDs; they do not pose a relevant risk for patients with...

Read More
June 1, 2018
UCB Receives CHMP Positive Opinion for Adjunctive Use of...

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for BRIVIACT(R...

Read More